Documentos de Académico
Documentos de Profesional
Documentos de Cultura
CARDIOLOGA
Relacin de potenciales problemas de seguridad (PPS) acordados con
cardiologa:
BIBLIOGRAFA:
1.
Cuzik J. Thorat M.A. Bossetti C. Estimates of benefits and harms of prophylactic use
of aspirin in the general population. Annals of oncology 2015;26:47-57
2.
American Geriatrics Society updated Beers Criteria for potentially inappropriate
medication use in older adults. Journal of the American Geriatrics Society.
2012;60(4):616-31.
3.
Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major
adverse cardiovascular events in patients with diabetes mellitus: a systematic review and
meta-analysis. Cardiovascular diabetology. 2011;10:25. Epub 2011/04/02.
4.
Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, et al. Aspirin for
the primary prevention of cardiovascular events: a systematic review and meta-analysis
comparing patients with and without diabetes. Diabetes care. 2009;32(12):2300-6. Epub
2009/09/11.
5.
De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al.
Association of aspirin use with major bleeding in patients with and without diabetes. JAMA
: the journal of the American Medical Association. 2012;307(21):2286-94. Epub
2012/06/19.
6.
Grupo de trabajo para la elaboracin de la Gua de Prctica Clnica sobre Diabetes
tipo 2. Gua de Prctica Clnica sobre Diabetes tipo 2. Madrid: Plan Nacional para el SNS
del MSC. Agencia de Evaluacin de Tecnologas Sanitarias del Pas Vasco; 2008. Guas de
Prctica Clnica en el SNS: OSTEBA, No 2006/08.
7. Understanding task Force Draft Recommendations: Aspirin to prevent cardiovascular
Disease (CVD) and cancer. U.S. Preventive Services Task Force. 2015
BIBLIOGRAFA:
1.
Spencer F A, Prasad M, Vandvik P O, Chetan D, Zhou Q, Guyatt G et al. Longerversus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement. A
systematic review and meta-analysis. Ann Intern Med. 2015;163:118-126
2.
Navarese E P, Andreotti F, Schulze V, Kolodziejczak M, Buffon A et al. Optimal
duration of dual antiplatelet therapy after percutaneous coronary intervention with drug
eluting stents: meta-analysis of randomised controlled trials. BMJ 2015;350:h1618
3. Tullio Palmerini, Umberto Benedetto, Letizia Bacchi-Reggiani, Diego Della Riva,
Giuseppe Biondi-Zoccai, Fausto Feres et al, Mortality in patients treated with extended
duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and
Bayesian network meta-analysis of randomised trials. Lancet. 2015; 385: 237182
4.
Helfy G, Steg P G, Le Feuvre C, Georges J-L, Carrie D et al. Stopping or continuing
clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.
European Heart Journal. 0.1093/eurheartj/ehv481
BIBLIOGRAFA:
1.
Grupo de Trabajo para la elaboracin de la Gua de Prctica Clnica sobre el manejo
de los lpidos como factor de riesgo cardiovascular. Gua de Prctica Clnica sobre el
manejo de los lpidos como factor de riesgo cardiovascular. Osakidetza-Servicio Vasco de
Salud, editor. Vitoria-Gasteiz, 2014.
2.
Los lpidos como factor de riesgo cardiovascular: Tratamiento farmacolgico. INFAC
2014. 33(7): 38-43.
3.
NICE guideline: Cardiovascular disease: risk assessment and reduction, including
lipid modification. 2014
BIBLIOGRAFA:
1. ACE inhibitors in heart failure with reduced ejection fraction: Therapeutic use:
UpToDate, 2016.
2. Scotland NHS. Polypharmacy Guidance (March 2015)
3. Delgado Silveira E, Montero Errasquin B, Munoz Garcia M, Velez-Diaz-Pallares M,
Lozano Montoya I, Sanchez-Castellano C, et al. [Improving drug prescribing in the
elderly: A new edition of STOPP/START criteria.]. Revista espaola de geriatra y
gerontologa. 2014. Epub 2014/12/04. Mejorando la prescripcin de medicamentos en
las personas mayores: una nueva edicin de los criterios STOPP-START.
BIBLIOGRAFA:
1.
5
Proyecto Polimedicados AP AE - OSI Donostialdea 2016